Background: Febuxostat has been approved for the treatment of hyperuricemia in patients with/without gout.
Objectives: This meta-analysis and systematic review assessed the efficacy and tolerability of febuxostat in hyperuricemic patients with/without gout.
Methods: Major electronic databases were searched for articles of all publication years (up to February 2012), as were the Web sites of the American College of Rheumatology, the European League Against Rheumatism, and the Chinese State Food and Drug Administration, and clinicaltrials.gov for unpublished studies. Only randomized, controlled trials (RCTs) were included.
Results: Ten trials were included. A significantly greater proportion of patients achieved the target serum urate level (sUA ≤6.0 mg/dL) at the final visit in the febuxostat group compared with the placebo (OR = 235.73; P < 0.01) and allopurinol groups (OR = 3.14; P < 0.01). In subgroup analysis, the proportion of patients who achieved target sUA at the final visit was significantly greater in the febuxostat-treated group (40 mg/d) compared with the allopurinol-treated group (100-300 mg/d) (50.9% vs 45.6%; OR = 1.25; 95% CI, 1.05-1.49; P = 0.01). As the dosage was increased (40, 80, 120 mg/d), the proportion of patients who achieved target sUA in the febuxostat-treated group increased gradually (50.9%, 71.4%, 82%, respectively). There was no significant difference in the occurrence of adverse events (AEs) between the febuxostat- and allopurinol-treated groups.
Conclusion: Febuxostat was effective in reducing serum urate in hyperuricemic patients with/without gout, and febuxostat (40-120 mg/d) was more efficacious compared with allopurinol (100-300 mg/d). The doses of allopurinol to which febuxostat has been compared, although commonly prescribed, are low in the range of approved doses of allopurinol. The tolerability of febuxostat for the treatment of hyperuricemia with/without gout is similar to that of allopurinol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinthera.2012.12.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]Trifluoroiodomethane - Enabling Photoredox-mediated Radical [F]Trifluoromethylation for Positron Emission Tomography.
Angew Chem Int Ed Engl
September 2024
Dept. of Radiology and Nuclear Medicine Amsterdam UMC, location Vrije Universiteit, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
The development of new tracers for positron emission tomography (PET) is highly dependent on the available synthetic tools for their radiosynthesis. Herein, we present the radiosynthesis and application of [F]trifluoroiodomethane - the first reagent for broad scope radical [F]trifluoromethylation chemistry in high molar activity. CF FI can be prepared from [F]fluoroform with 67±5 % AY and >99 % RCP.
View Article and Find Full Text PDFRhabdomyolysis Associated With Febuxostat in a Non-Chronic Kidney Disease (CKD) Patient: Diagnostic and Management Challenges.
Cureus
June 2024
Internal Medicine, La Grange Memorial Hospital, Chicago, USA.
Rhabdomyolysis is a critical medical condition characterized by the rapid breakdown of muscle tissue, releasing substances such as myoglobin and creatine kinase into the bloodstream, potentially leading to acute kidney injury. The etiology includes trauma, exertion, genetic factors, infections, and adverse drug reactions. Febuxostat, a non-purine selective xanthine oxidase inhibitor used to manage hyperuricemia in gout patients, is typically well-tolerated but has been associated with rare instances of severe adverse reactions like rhabdomyolysis.
View Article and Find Full Text PDFEfficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
Am J Kidney Dis
November 2024
VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania; School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Rationale & Objective: We conducted a prespecified examination of the efficacy and safety of allopurinol and febuxostat administered using a treat-to-target strategy in trial participants with chronic kidney disease (CKD).
Study Design: Prespecified subcohort analysis of a randomized controlled trial.
Setting & Participants: A substudy of the STOP Gout Trial in participants with CKD.
Mechanisms and rationale for uricase use in patients with gout.
Nat Rev Rheumatol
October 2023
Université Paris Cité, UFR de Médecine, Paris, France.
Xanthine oxidase inhibitors such as allopurinol and febuxostat have been the mainstay urate-lowering therapy (ULT) for treating hyperuricaemia in patients with gout. However, not all patients receiving oral ULT achieve the target serum urate level, in part because some patients cannot tolerate, or have actual or misconceived contraindications to, their use, mainly due to comorbidities. ULT dosage is also limited by formularies and clinical inertia.
View Article and Find Full Text PDF[Prevention of urolithiasis using febuxostat in patients with metabolic syndrome].
Urologiia
July 2023
FGBVOU VO S. M. Kirov Military Medical Academy of the Ministry of Defense of Russian Fed-eration, Saint Petersburg, Russia.
Introduction: Urolithiasis is a chronic highly recurrent disease. The development of new methods of its pathogenetic treatment and prevention is a priority task of practical urology.
Aim: To evaluate the clinical efficiency and safety of Febuxostat-SZ and to develop the rec-ommendations for its use in patients with uric acid stones.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!